Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Scripts who wrote (810)	2/11/2000 10:54:00 AM
From: Ian@SI	Read Replies (2) \| Respond to of 1321

Ed, Obviously I'm mistaken re the 17th. Part is probably a bad memory. Part of my error is treating 180 days as being 6 months. 6 Months from Aug 16th would take us to Feb 16th. The panel's conclusions will be taken into consideration by the FDA as it completes its review of the New Drug Application (NDA) for Visudyne therapy, which was submitted on August 16, 1999. I don't know how to see the FDA's meeting / review schedule; nor do I know a definitive source for getting that specific information. I may pick up the phone and ask Elayne or Tamara. If so, I'll report back whatever I learn. Ian.